In a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According to ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on QuidelOrtho (QDEL – Research Report) and Palatin ...

This page features the latest news about the Actinium Pharmaceuticals stock. ATNM stock touches 52-week low at $1.17 amid market challenges In a challenging market environment, Actinium ...

As interest in radiopharmaceuticals has soared, supply chains have struggled to keep up. The alpha-emitter actinium-225, for ...

France’s Framatome and IBA (Ion Beam Applications, Euronext), a specialist in particle accelerator technology and ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Ken Herrmann, MD, MBA, from the Universitätsklinikum Essen (Germany), and Johannes Czernin, MD, from the David Geffen School ...

With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production. Mr. Oliverio joins Actineer with over three ...

PET scans use fluorodeoxyglucose (FDG), a radioactive form of glucose, to show how aggressively tumours consume glucose ...